TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
RPH Pharmaceuticals AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
445,770
|
333,688
|
218,318 |
| Financial expenses |
31,369
|
32,496
|
16,935 |
| Earnings before taxes |
131,878
|
45,004
|
35,184 |
| EBITDA |
137,422
|
110,727
|
70,491 |
| Total assets |
267,073
|
324,300
|
284,417 |
| Current assets |
76,178
|
109,699
|
89,600 |
| Current liabilities |
210,094
|
282,370
|
241,479 |
| Equity capital |
53,966
|
38,969
|
40,174 |
| - share capital |
103
|
101
|
95 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
20.2%
|
12.0%
|
14.1% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
29.6%
|
13.5%
|
16.1% |
| Return on assets (ROA) |
61.1%
|
23.9%
|
18.3% |
| Current ratio |
36.3%
|
38.8%
|
37.1% |
| Return on equity (ROE) |
244.4%
|
115.5%
|
87.6% |
| Change turnover |
106,066
|
99,879
|
48,236 |
| Change turnover % |
31%
|
43%
|
28% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.